Condition: Cardiotoxicity · Pulmonary Toxicity · Thymus Neoplasms · Sponsor: Ass. Prof. Jan Nyman
This is a multicentre non-randomized phase II study of proton beam radiotherapy in patients with thymic epithelial tumours (i.e. thymoma and thymic carcinoma) in the post-operative setting or in inoperable patients with localized disease. Patients not willing or for any reason unsuitable to undergo proton treatment will be asked to participate in a follow-up assessment after the regular photon treatment in the same manner as the included patients. Primary endpoints are:Toxicity (e.g. cardiac and pulmonary toxicity) and Local control at 5 year Secondary endpoints: PFS, Overall survival, Quality of life, measured by EORTC QLQ 30 + LC 13 and relapse pattern
This description comes directly from the study's public registry record.
Jan Nyman, Ass.prof. · +46313421000 · jan.nyman@oncology.gu.se
Andreas Hallqvist, MD, PhD · +46739845114 · andreas.hallqvist@vgregion.se
Always discuss trial participation with your own doctor first.
| Department of Oncology, Norrlands Universitetssjukhus | Umeå, Norrland, Sweden | Recruiting |
| Department of Oncology, Karolinska University Hospital | Stockholm, Stockholm County, Sweden | Not Yet Recruiting |
| Department of Oncology, Sahlgrenska University Hospital | Gothenburg, Västra Götaland County, Sweden | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04822077